2024 ASH Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Summaries & Highlights
2024 ASH Annual Meeting Insights Hub
Tandem 2025 Summary: Hematologic Toxicities Following CAR-T in Lymphoma Patients
FEATURING
Liffy Cherian
- 15 views
- February 28, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Targeted Medical Therapies for Vascular Anomalies
FEATURING
Alexandra Borst
- 31 views
- February 6, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for 1L CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 178 views
- February 5, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for R/R CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 39 views
- February 5, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Late Complications and Long-Term Care for Adult Pts Following CAR-T Therapy
FEATURING
Michael Bishop
- 68 views
- January 31, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CMML Highlights
FEATURING
Douglas Tremblay
- 216 views
- January 30, 2025
- 3
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: FL Highlights
FEATURING
Paolo Strati
- 201 views
- January 30, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph- ALL
FEATURING
Fadi Haddad
- 178 views
- January 21, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph+ ALL
FEATURING
Fadi Haddad
- 119 views
- January 21, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dose Optimization of Inotuzumab Ozogamicin in Adult Patients With R/R ALL
FEATURING
Daniel J. DeAngelo
- 38 views
- January 15, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Patient-Reported QoL Outcomes With Venetoclax-Based 1L Combinations in CLL
FEATURING
Moritz Fürstenau
- 78 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CLL Highlights
FEATURING
Alexey Danilov
- 285 views
- January 15, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Dose Optimization of Inotuzumab Ozogamicin in Adult Patients With R/R ALL
FEATURING
Daniel J. DeAngelo
- 3 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: The POD24 Challenge in FL - Where Do We Go From Here?
FEATURING
Carla Casulo
- 57 views
- January 14, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AL Amyloidosis and SMM
FEATURING
Samer Al Hadidi
- 194 views
- January 10, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implications
FEATURING
Samer Al Hadidi
- 455 views
- January 10, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Myeloma Highlights and Impact on Practice
FEATURING
Hamza Hashmi
- 1,269 views
- January 9, 2025
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in CML
FEATURING
Jay Yang
- 332 views
- January 9, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Making
FEATURING
Aurore Perrot
- 180 views
- January 6, 2025
- 3
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlights From ASH
FEATURING
Joshua Zeidner
- 446 views
- December 30, 2024
- 5
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,276 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid Disease
FEATURING
Hugo F. Fernandez
- 265 views
- December 23, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Adult ALL and Implications for Practice
FEATURING
Ryan Cassaday
- 349 views
- December 23, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Bone Marrow Failure Disorders
FEATURING
Phillip Scheinberg
- 426 views
- December 19, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Overview of Non-Surgical Management of Heavy Menstrual Bleeding
FEATURING
Allison Wheeler
- 97 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Quantifying Heavy Menstrual Bleeding
FEATURING
Allison Wheeler
- 46 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How
FEATURING
Jean-Jacques Kiladjian
- 302 views
- December 17, 2024
- 4
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for Extended VTE Management
FEATURING
Jordan Schaefer
- 456 views
- December 16, 2024
- 2
Lymphoma
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome for Bispecific Antibody Therapy in R/R LBCL
FEATURING
Evgenii Shumilov
- 95 views
- February 14, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: FL Highlights
FEATURING
Paolo Strati
- 201 views
- January 30, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: The POD24 Challenge in FL - Where Do We Go From Here?
FEATURING
Carla Casulo
- 57 views
- January 14, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Odronextamab in R/R DLBCL Post-CAR T-Cell Progression - Primary Analysis of ELM-1 Study
FEATURING
Matthew Matasar
- 112 views
- January 8, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin Into Radiation-Free Treatment of Early Stage cHL
FEATURING
Ann LaCasce
- 259 views
- January 6, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Cell Failure for Aggressive BCL
FEATURING
Megan Melody
- 172 views
- December 19, 2024
- 4
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dynamics of ctDNA and Outcomes With Liso-cel in R/R LBCL - Transcend NHL-001 Study
FEATURING
Caroline Lee
- 48 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: CAR T-Cell Therapy in Octogenarians With R/R LBCL
FEATURING
Caroline Lee
- 69 views
- December 18, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L DLBCL
FEATURING
Gilles Salles
- 221 views
- December 18, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Loncastuximab Tesirine and Rituximab in High-Risk R/R Follicular Lymphoma
FEATURING
Juan Alderuccio
- 18 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Optimizing Tafa-Len in R/R DLBCL - GELTAMO Real-World Study
FEATURING
Antonio Gutierrez
- 51 views
- December 16, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With MCL - MAVO Phase 1/2 Study
FEATURING
Austin Kim
- 36 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Real-World Outcomes With Evolving Management of CRS in CAR-T Therapy for NHL
FEATURING
Radhika Bansal
- 22 views
- December 13, 2024
Leukemia
2024 ASH Annual Meeting Insights Hub
Updates From ASH 2024: Dynamics of Overall and Organ-Specific Responses to Axatilimab in cGVHD - Analysis From the AGAVE-201
FEATURING
Christopher Graham
- 11 views
- March 18, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + "7+3" Induction Chemo in Newly Diagnosed AML Induces High MRD- Response Rates
FEATURING
Ioannis Mantzaris
- 7 views
- March 18, 2025
2024 ASH Annual Meeting Insights Hub
Tandem 2025 Summary: Hematologic Toxicities Following CAR-T in Lymphoma Patients
FEATURING
Liffy Cherian
- 15 views
- February 28, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for 1L CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 178 views
- February 5, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for R/R CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 39 views
- February 5, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CMML Highlights
FEATURING
Douglas Tremblay
- 216 views
- January 30, 2025
- 3
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Overall Survival Outcomes of Real-World Treatment Sequences in CLL/SLL Patients
FEATURING
Joanna Rhodes
- 29 views
- January 21, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph- ALL
FEATURING
Fadi Haddad
- 178 views
- January 21, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph+ ALL
FEATURING
Fadi Haddad
- 119 views
- January 21, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dose Optimization of Inotuzumab Ozogamicin in Adult Patients With R/R ALL
FEATURING
Daniel J. DeAngelo
- 38 views
- January 15, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Patient-Reported QoL Outcomes With Venetoclax-Based 1L Combinations in CLL
FEATURING
Moritz Fürstenau
- 78 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CLL Highlights
FEATURING
Alexey Danilov
- 285 views
- January 15, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Dose Optimization of Inotuzumab Ozogamicin in Adult Patients With R/R ALL
FEATURING
Daniel J. DeAngelo
- 3 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in CML
FEATURING
Jay Yang
- 332 views
- January 9, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Prevalence of BTK & PLCG2 Mutations in BTKi Treated CLL Patients Who Experience Disease Progression - A Meta-Analysis
FEATURING
Stefano Molica
- 75 views
- December 30, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlights From ASH
FEATURING
Joshua Zeidner
- 446 views
- December 30, 2024
- 5
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dasatinib + Inotuzumab Ozogamicin-Based Induction for 1L Ph+ ALL
FEATURING
Anand Patel
- 36 views
- December 30, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,276 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid Disease
FEATURING
Hugo F. Fernandez
- 265 views
- December 23, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Adult ALL and Implications for Practice
FEATURING
Ryan Cassaday
- 349 views
- December 23, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Impact of Time From Diagnosis to Treatment on Outcomes of Adults With AML Treated With HMA + Ven - COMMAND Consortium Study
FEATURING
Samuel Yates
- 29 views
- December 20, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in 1L CLL - 5yr Follow up, Retreatment, and MRD Kinetics
FEATURING
Jake Soumerai
- 137 views
- December 20, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results From the BGB-11417-101 Study
FEATURING
Jake Soumerai
- 86 views
- December 20, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL
FEATURING
Sumit Gupta
- 164 views
- December 19, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Blinatumomab & Ponatinib for Adults With Newly Diagnosed Ph+ ALL - Updated Results and Predictors of Relapse
FEATURING
Nicholas Short
- 44 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: 1L Triplet Therapy With Ven + HMA + FLT3i in Adults With FLT3-mut AML - Long-Term Survival & Cytogenetic/Molecular Patterns of Relapse
FEATURING
Nicholas Short
- 55 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: E1910 Update - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients With Ph- B-ALL
FEATURING
Nikolai Podoltsev
- 76 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ven + Aza for Molecular Relapse After 1L Intensive Chemo in NPM1-Mut or CBF AML - A FILO Study
FEATURING
Jules Higué
- 18 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- 97 views
- December 18, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 CLL12 Trial - Impact of Ibrutinib on QoL in Pts With Early-Stage, Asymptomatic CLL
FEATURING
Ellinor Goergen
- 22 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 70 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Venetoclax +/- Obinutuzumab vs. CIT for 1L CLL
FEATURING
Jennifer Brown
- 201 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: GLOW Study 64-Month Follow-Up - 1L Ibrutinib + Venetoclax vs. Chlorambucil + Obinutuzumab in Elderly/Frail CLL
FEATURING
Carsten Utoft Niemann
- 22 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- 74 views
- December 16, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Epcoritamab Monotherapy in R/R CLL - Expansion and Optimization Cohort Results From EPCORE CLL-1
FEATURING
Alexey Danilov
- 32 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 351 views
- December 16, 2024
- 5
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 72 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML
FEATURING
Maria Amaya
- 129 views
- December 13, 2024
- 1
Myeloma
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in NDMM Patients With Renal Failure - A Flatiron Real-World Analysis
FEATURING
Adeel Khan
- 63 views
- February 28, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxicity & Durable Responses to Ide-Cel Therapy for R/R MM
FEATURING
Doris Hansen
- 40 views
- January 21, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain Amyloidosis - Ph2 European Myeloma Network Study
FEATURING
Efstathios Kastritis
- 36 views
- January 13, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 ANDROMEDA - Subcutaneous Dara + VCd in Newly Diagnosed Light-Chain Amyloidosis
FEATURING
Efstathios Kastritis
- 56 views
- January 13, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AL Amyloidosis and SMM
FEATURING
Samer Al Hadidi
- 194 views
- January 10, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implications
FEATURING
Samer Al Hadidi
- 455 views
- January 10, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Myeloma Highlights and Impact on Practice
FEATURING
Hamza Hashmi
- 1,269 views
- January 9, 2025
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: A High-Fiber Diet in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
FEATURING
Urvi Shah
- 14 views
- January 9, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Results of a Randomized Clinical Trial
FEATURING
Urvi Shah
- 233 views
- January 9, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Safety and Efficacy of Cilta-Cel vs. Ide-Cel in R/R MM
FEATURING
Doris Hansen
- 47 views
- January 8, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Making
FEATURING
Aurore Perrot
- 180 views
- January 6, 2025
- 3
2024 ASH Annual Meeting Insights Hub
Talquetamab as a Bridging Therapy to BCMA CAR-T in RRMM
FEATURING
Binod Dhakal
- 149 views
- December 31, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T Therapy - Prevalence and Mutational Landscape
FEATURING
Johannes Waldschmidt
- 112 views
- December 31, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Efficacy of Anti-BCMA CAR-T in Myeloma Patients Previously Treated With Bispecific Antibodies - Results From a Multi-Center Registry
FEATURING
Johannes Waldschmidt
- 152 views
- December 31, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: A Dexamethasone Sparing-Regimen w/ Dara & Len for Frail 1L MM Patients - IFM2017-03 Ph3 Trial
FEATURING
Salomon Manier
- 25 views
- December 24, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Effectiveness of Immunoglobulin Replacement on Hypogammaglobulinemia & Infectious Complications in MM Patients
FEATURING
Elizabeth O'Donnell
- 56 views
- December 23, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Genomic Determinants of Outcomes in MM With t(11;14) Treated With Venetoclax
FEATURING
Marcella Karddoura
- 14 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Maintenance With Teclistamab +/- Len or Len Alone in NDMM Post-ASCT - MajesTEC-4/EMN30 Ph3 Safety Run-in
FEATURING
Elena Zamagni
- 26 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: VRD Consolidation and Len Maintenance in MM - Long-Term EMN02/HOVON95 Ph3 Study Results
FEATURING
Pieter Sonneveld
- 42 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L ASCT - KarMMa-2 Trial Follow-Up
FEATURING
Barry Paul
- 63 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Optimizing Therapy Duration for Transplant-Ineligible NDMM - Long-Term UK Myeloma XI Data
FEATURING
Charlotte Pawlyn
- 62 views
- December 16, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone in RRMM
FEATURING
Muhamed Baljevic
- 76 views
- December 16, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From CAR-PRISM Study
FEATURING
Omar Nadeem
- 46 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Analyses of MRD Negativity Dynamics in the Phase 3 IMROZ Study - Isa-VRd in Patients With Newly Diagnosed MM
FEATURING
Robert Z. Orlowski
- 121 views
- December 13, 2024
- 3
2024 ASH Annual Meeting Insights Hub
Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for R/R MM in Community Settings - Focusing on Bispecific Antibody Therapy
FEATURING
Benjamin Derman
- 13 views
- December 13, 2024
MDS & MPN
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
FEATURING
Barbara Mora
- 93 views
- February 14, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Oral Decitabine-Cedazuridine in Pts With TP53mut MDS - An Analysis From Ph2 & 3 Trials
FEATURING
Samuel Urrutia
- 45 views
- January 17, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Ruxolitinib for JAK Inhibitor–Naïve Patients With MF
FEATURING
John Mascarenhas
- 121 views
- December 27, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available Therapy in JAK Inhibitor R/R MF
FEATURING
John Mascarenhas
- 54 views
- December 27, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Worsening Anemia Treated With Ruxolitinib - Retrospective US Real-World Analysis
FEATURING
Andrew Kuykendall
- 69 views
- December 24, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-World Mayo Clinic Series
FEATURING
Talha Badar
- 112 views
- December 24, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,276 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid Disease
FEATURING
Hugo F. Fernandez
- 265 views
- December 23, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Targeting Anemia in LR-MDS
FEATURING
Matteo Della Porta
- 37 views
- December 23, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: HRQoL With Luspatercept vs. Epoetin Alfa in RBC Transfusion-Dependent Lower-Risk MDS - COMMANDS Study
FEATURING
Esther Oliva
- 26 views
- December 20, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Hepcidin Mimetic Rusfertide in PV - Final Results of the Revive Study
FEATURING
Aaron Gerds
- 69 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 EPO-PRETAR Trial - Early vs. Late Treatment With ESA in Lower-Risk Anemic MDS Patients
FEATURING
Sophie Park
- 17 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: MPN Highlights and Clinical Implications
FEATURING
Douglas Tremblay
- 811 views
- December 18, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How
FEATURING
Jean-Jacques Kiladjian
- 302 views
- December 17, 2024
- 4
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Effect of Prior Treatments on Imetelstat in Transfusion-Dependent Pts With ESA-Relapsed or Refractory/Ineligible LR-MDS
FEATURING
Uwe Platzbecker
- 29 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Importance of Achieving Hb ≥10 g/dL in Transfusion-Dependent ESA-Naïve LR-MDS Pts Treated With Luspatercept - COMMANDS Trial
FEATURING
Valeria Santini
- 34 views
- December 16, 2024
- 1
Benign Hematology
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Targeted Medical Therapies for Vascular Anomalies
FEATURING
Alexandra Borst
- 31 views
- February 6, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients With cGVHD in the US
FEATURING
Catherine Lee
- 28 views
- February 5, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Eltrombopag vs. Standard 1L Treatment in Newly Diagnosed Pediatric ITP - Ph3 PINES Study
FEATURING
Kristin Shimano
- 26 views
- January 17, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Final Analysis of Pegylated Interferon in PV and ET Patients
FEATURING
Lucia Masarova
- 122 views
- December 20, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Bone Marrow Failure Disorders
FEATURING
Phillip Scheinberg
- 426 views
- December 19, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Overview of Non-Surgical Management of Heavy Menstrual Bleeding
FEATURING
Allison Wheeler
- 97 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Quantifying Heavy Menstrual Bleeding
FEATURING
Allison Wheeler
- 46 views
- December 19, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: De-Escalated PTCy & Ruxolitinib for GVHD Prophylaxis in Older Patients Undergoing RIC AlloHCT
FEATURING
Sameem Abedin
- 47 views
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for Extended VTE Management
FEATURING
Jordan Schaefer
- 456 views
- December 16, 2024
- 2